Overview

Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children

Status:
Completed

Trial end date:
2018-05-22

Target enrollment:

Participant gender:

Summary

To characterize the pharmacokinetic profile of rivaroxaban administered as granules for suspension formulation and to document safety and tolerability

Phase:

Phase 1

Details

Lead Sponsor:

Bayer

Collaborator:

Janssen Research & Development, LLC

Treatments:

Rivaroxaban